Restricted accessReview articleFirst published online 2023-11
Multifocal bladder nephrogenic adenoma following repeated intravesical onabotulinumtoxinA (Botox ® ) injection for refractory overactive bladder. Case report and literature review
NittiVDmochowskiRHerschornS, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a Phase 3, randomized, placebo controlled trial. J Urol2013; 189: 2186–2193.
2.
Eldred-EvansDSahaiA.Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol2017; 9: 3–10.
3.
VenyoAK.Nephrogenic adenoma of the urinary bladder: a review of the literature. Int Sch Res Notices2015; 2015: 704982.
4.
YiYWuACameronA.Nephrogenic adenoma of the bladder: a single institution experience assessing clinical factors. Int Braz J Urol2018; 44: 506–511.
5.
ScelziSGiubileiGBartolettiR, et al. Nephrogenic adenoma of bladder after ibuprofen abuse. Urology2004; 64: 1030.e13–e14.
6.
WatanabeTMasagoTMiyagawaI.Apoptotic action of botulinum toxin on detrusor muscle in rats. Urol Int2010; 84: 341–346.
7.
ApostolidisAJacquesTSFreemanA, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol2008; 53: 1245–1253.
